Randomized Controlled Trial

A Randomized Controlled Trial (RCT) is the gold standard study design for establishing clinical efficacy and safety. Participants are randomly allocated via computer generation into two or more parallel groups: an experimental intervention group and a control group (receiving a placebo, standard-of-care active comparator, or no treatment). When conducted with double-blinding (neither participants nor investigators know group assignments), RCTs minimize selection bias, confounding, and observer bias.

Inside Peptides awards its highest evidence tier (Strong Evidence) only to clinical claims backed by adequately powered Phase 3 randomized controlled trials.

Randomisation is what lets a trial show cause and effect. When chance decides who gets the treatment and who gets the comparison, differences in age, health, motivation and lifestyle tend to balance out between groups, so a difference in outcomes can be credited to the treatment. Before-and-after stories, testimonials and uncontrolled case series cannot do this, which is why they rank far below RCTs in evidence hierarchies.

For peptides, the gap between RCT-tested and untested compounds is stark. GLP-1 drugs have been compared head to head in large trials: SURPASS-2 randomly assigned 1,879 people with type 2 diabetes to tirzepatide or semaglutide. By contrast, a 2025 systematic review of BPC-157 found no randomised trials in its musculoskeletal evidence base, so claims about it rest on animal studies and anecdote.

Not every RCT is equally strong. Readers should look at size, duration, blinding, funding and whether the outcome matters to patients. SURPASS-2 and STEP 8, for instance, compared their active drugs open-label, meaning participants knew which drug they received, and SURPASS-2 was funded by Eli Lilly, the maker of tirzepatide. That does not invalidate the results, but it is context worth knowing.

“Every RCT is double-blind”

Randomisation and blinding are separate features. Some trials are open-label, especially when comparing two active drugs that are given differently. In STEP 8, the semaglutide versus liraglutide comparison was open-label, while each active drug was double-blinded against a matching placebo. Open-label trials are still randomised, but they are more vulnerable to bias when outcomes are subjective.

“One RCT settles the question”

A single trial can be affected by chance, its particular population or design choices. Confidence grows when several independent RCTs point the same way, ideally pooled in a systematic review or meta-analysis. Results in one group, such as adults with type 2 diabetes, also may not apply to people without diabetes or to other conditions.

“A ‘clinical study’ is the same as an RCT”

Many studies in humans are not randomised: case reports, case series, retrospective chart reviews and uncontrolled pilot studies. These can generate ideas but cannot reliably separate a treatment’s effect from placebo response, natural recovery or bias. When a seller says a peptide is “clinically studied”, ask whether any of the studies were randomised and controlled.

Why are randomized controlled trials the gold standard?

Random allocation spreads both known and unknown differences between participants evenly across groups, and a control group shows what happens without the treatment. Together these allow a difference in outcomes to be attributed to the treatment itself rather than to chance, placebo effects or the type of person who chose it. Blinding, when used, further reduces bias.

What is the difference between placebo-controlled and active-comparator trials?

A placebo-controlled trial compares a treatment with an inactive look-alike and shows whether it works at all. An active-comparator trial compares it with an existing treatment and shows whether it works better, worse or similarly. SURPASS-2 compared tirzepatide with semaglutide, and STEP 8 compared semaglutide with liraglutide while also including placebo groups.

Are there randomized controlled trials of BPC-157?

A 2025 systematic review of BPC-157 for musculoskeletal injuries found 35 preclinical studies and a single human study, which was a small retrospective report rather than a randomised trial. The review found no clinical safety data. Claims that BPC-157 is proven to work in people are therefore not supported by RCT evidence, and it is not FDA-approved.

What does open-label mean in a clinical trial?

Open-label means participants and investigators know which treatment each person is receiving. It is common when blinding is impractical, for example when two drugs are given in visibly different ways. Open-label trials can still be randomised, but knowing the treatment can influence how people report symptoms, so objective outcomes such as HbA1c or body weight are more reliable in them.